Does the Use of Ropivacaine Facilitates Cholecystectomy by Laparoscopy in Ambulatory Surgery?

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02085902

Acronym

VesiRop

Enrollment

120

Registered

2014-03-13

Start date

2014-03-31

Completion date

2015-05-31

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystectomy, Laparoscopy

Brief summary

Since the recommendations of the French Society of Digestive Surgery 2010, cholecystectomy can be performed as outpatient surgery. This approach is difficult in many centers because of post operative pain and nausea/vomiting. The use of postoperative morphine may be responsible for the state of nausea. The use of ropivacaine allows a reduction of the morphine consumption and thus may allow the patient to have their surgery as an outpatient. Currently, ropivacaine is used randomly during the investigators surgeries. Initially, it was used for the infiltration holes trocar. In recent years, ropivacaine is used for the reduction of intra-abdominal postoperative pain. Its use is made of parietal surgery ( hernia ) in cholecystectomy and colonic surgery. This mode of administration is allowed to view the many publications made on this subject. Its use in the investigators daily surgery, however, has not been evaluated in ambulatory surgery.

Interventions

DRUGRopivacaine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Programmed Cholecystectomy * Laparoscopy * Man and woman * ≥ 18 * ASA 1 or 2 * Not living alone * Patient receiving social security coverage * Signature of Informed Consent Form

Exclusion criteria

* Cholecystectomy emergency * Patient minor * Pregnant woman (pregnancy test) or during breastfeeding * Conversion to laparotomy * Patient anticoagulant curative dose * Living alone * Patient addict * Peptic Ulcer * Refusal to enter the protocol * Chronic requiring analgesics long-term * Immunosuppression * Long-term Treatment with corticosteroids * Discovery intraoperative calculation in the bile duct * Contraindication to ropivacaine (see cons-indications to ropivacaine) * Hypersensitivity to study treatment or concomitant medications anesthesia * Cardiac or unbalanced epileptic patients (due to the risk of cardiovascular and neurological local anesthetics) * Patients ASA ≥ 3 * Patient \<50 kg

Design outcomes

Primary

Measure	Time frame
Time to discharge patient after surgery	6 hours postoperative

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026